IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Merck & Co., Inc.

Q2 2026 Holdings

Filed 2026-08-07 | 13 holdings | $526.4M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Personalis Inc(PSNL)COM71535D106$188.2M14,044,94335.8%
Moderna Inc(MRNA)COM60770K107$161.6M2,308,19030.7%
Kymera Therapeutics Inc(KYMR)COM501575104$88.5M772,16516.8%
Aktis Oncology Inc(AKTS)COM01021M104$30.7M952,8445.8%
Eikon Therapeutics Inc(EIKN)COM282564103$21.7M1,666,6664.1%
Entrada Therapeutics Inc(TRDA)COM29384C108$12.8M1,739,7682.4%
Sutro Biopharma Inc(STRO)COM869367201$9.0M272,3511.7%
Alector Inc(ALEC)COM014442107$7.1M3,545,7191.4%
Evaxion Biotech A/S(EVAX)SPONSORED ADS29970R303$3.8M1,214,1260.7%
Viridian Therapeutics Inc(VRDN)COM92790C104$1.7M93,4140.3%
Xilio Therapeutics Inc(XLO)COM98422T209$1.0M105,9820.2%
Tuhura Biosciences Inc(HURA)COM898920103$45.5K19,4450.0%
Neuphoria Therapeutics Inc(NEUP)COM64136E102$43.8K10,0270.0%